X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

May 05, 2020

Timelines for Medical Device Regulation and Risk Assessment for Nitrosamines in Europe Extended

We are living in very unpredictable times. The virus SARS-CoV-2 is keeping the global pharmaceutical industry, including regulatory agencies, very busy. The whole industry is working together in the development of treatments and vaccines. The process of getting these treatments approved and to patients as quickly as possible requires the undivided attention of regulatory agencies, such as the FDA and EMA. As a result, the following deadlines have been extended for certain other requirements.
Bettine Boltres

Bettine Boltres, PhD.

Principal Scientific Affairs, Packaging & Delivery Systems